U.S. stocks mixed ahead of Fed decision; General Mills retreatseyed
Procept Biorobotics Corp stock reached a 52-week low, touching 37.07 USD. According to InvestingPro data, the company maintains a strong financial position with a current ratio of 9.21 and more cash than debt on its balance sheet. This milestone marks a significant downturn for the company, reflecting a challenging period over the past year. The stock has experienced a sharp decline, with a 1-year change of -53.93%, despite impressive revenue growth of 55.71% over the last twelve months. This drop underscores the difficulties faced by Procept Biorobotics in maintaining investor confidence and market stability. The company’s performance contrasts with broader market trends, raising questions about its strategic direction and future prospects. InvestingPro analysis reveals seven analysts have revised their earnings downward for the upcoming period, with the company not expected to be profitable this year. Get deeper insights with InvestingPro’s comprehensive research report, available for over 1,400 US stocks.
In other recent news, Procept BioRobotics reported its second-quarter 2025 earnings, surpassing expectations with an earnings per share (EPS) of -$0.35, compared to the forecasted -$0.41. The company also exceeded revenue projections, reaching $79.2 million against an anticipated $76.12 million. Despite these positive financial results, the company faced a mixed response from analysts. Oppenheimer upgraded Procept BioRobotics from Perform to Outperform, citing an attractive risk-reward scenario for long-term growth investors and setting a price target of $60.00. Conversely, Wells Fargo adjusted its price target for the company from $75.00 to $58.00, maintaining an Overweight rating. This adjustment was due to management’s revised expectations regarding system replacements, which are now not anticipated in the second half of 2025. These developments highlight the varied perspectives on Procept BioRobotics’ future performance.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.